Jupiter Life Line Hospitals expansion and occupancy gains to support margin recovery

Investment View and Valuation

PL Research maintains a BUY rating on Jupiter Life Line Hospitals and raises the target price to Rs 360 from Rs 320. The broker believes growth can sustain over the medium term as occupancy and margins improve at the Pune and Indore hospitals, while strategic greenfield expansion in densely populated Western India micro-markets builds a larger platform.

PL Research highlights the company's operational efficiency in the competitive Mumbai Metropolitan Region and its approximately 20 per cent revenue and EBITDA CAGR over FY23-FY26. The target price is based on 26 times FY28E EV/EBITDA.

Q1 FY27 Financial Performance

Jupiter Life Line Hospitals reported Q1 FY27 consolidated revenue of Rs 4,110 million, up 16 per cent year-on-year and broadly in line with PL Research's estimate. EBITDA rose 1 per cent year-on-year to Rs 793 million, which was 5 per cent below the broker's Rs 837 million estimate. EBITDA margin contracted 290 basis points year-on-year and 370 basis points quarter-on-quarter to 19.3 per cent.

Adjusted for the loss at the newly operational Dombivli unit, EBITDA growth was 13 per cent year-on-year. Reported adjusted PAT declined 15 per cent year-on-year, reflecting higher depreciation and finance costs associated with Dombivli. Indore EBITDA declined about 7 per cent year-on-year due to pre-expansion expenditure, including doctor hiring and team build-up.

Operating Indicators

Operating indicators were constructive. Q1 FY27 ARPOB increased 9 per cent year-on-year to Rs 73,500 per day, supported by improved case mix, insurance renegotiations and inflation-linked pricing. Occupancy declined 50 basis points year-on-year to 59.6 per cent after new bed additions, but was 61.7 per cent excluding Dombivli, an increase of 160 basis points year-on-year.

In-patient volumes grew 7 per cent year-on-year to 14,200, while out-patient volumes rose 13 per cent to 2,77,300. Average length of stay was 3.76 days.

Capacity Expansion and Hospital Ramp-up

Management remains on track to expand capacity to approximately 2,900 beds by adding around 1,500 beds through four greenfield hospitals in Dombivli, Pune South, Mira Road and BKC over the next four to five years.

Around 200 beds are operational at the 500-bed Dombivli hospital, with fit-outs complete for another 100 beds. Dombivli occupancy is around 25-30 per cent, insurance empanelments are pending, and monthly fixed costs are Rs 60-70 million. Management expects EBITDA breakeven in 1.5-2 years and guides for a FY27 monthly EBITDA loss of Rs 20-30 million. PL Research factors in a Rs 300 million Dombivli EBITDA loss in FY27 and positive EBITDA of Rs 120 million in FY28. Oncology services at Dombivli are scheduled for commissioning by end-FY27.

Thane operates near maturity at around 75 per cent occupancy, leaving pricing as its principal incremental growth lever. Pune occupancy is around 60 per cent, leaving about 15 per cent headroom to mature occupancy, while its margin profile is broadly comparable with Thane. Indore occupancy is around 50 per cent and management is focused on ramping utilisation through FY27.

Management Outlook and Estimates

Management expects ARPOB growth of around 10 per cent year-on-year through case-mix improvement and payer-contract repricing. The company acquired an IV fluids manufacturing entity to improve pharmacy procurement efficiency and margins, rather than to enter pharmaceutical manufacturing.

Management expects capex to be largely funded by internal accruals and existing cash, with debt required later in the investment cycle and within the board-approved 3.0 times EBITDA leverage ceiling.

PL Research has reduced FY27E and FY28E sales estimates by 3.7 per cent and 1.6 per cent, respectively, while EBITDA estimates are broadly unchanged, down 0.8 per cent and 0.4 per cent. The broker forecasts FY26-FY28E EBITDA and PAT CAGR of 17 per cent and 10 per cent, respectively.

Key Execution Considerations

• The pace of Dombivli occupancy ramp-up and completion of insurance empanelments.
• Dombivli's initial operating losses and the timing of its EBITDA breakeven.
• Indore's expansion-related costs and utilisation ramp-up.
• Successful delivery of the wider greenfield bed-addition programme.